Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Hansoh Approved for China Launch of Ameile as Second-Line NSCLC Treatment

publication date: Mar 19, 2020

Jiangsu Hansoh Pharma has been approved to market Ameile (almonertinib) in China to treat non-small cell lung cancer (NSCLC). The once-daily tablets are aimed at NSCLC patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive disease who have progressed after another EGFR tyrosine kinase inhibitor therapy. Hansoh says Ameile is the second 3rd generation EGFR TKI approved for the indication. Hansoh completed a $1 billion IPO in Hong Kong during 2019. More details....

Stock Symbol: (HK: 3692)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.